Crizotinib

  (krih-ZOH-tih-nib)

This page contains brief information about crizotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Xalkori
FDA Approved:		Yes

FDA Approval for Crizotinib

Crizotinib is approved to treat:

• Non-small cell lung cancer that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients who have a certain type of chromosome change that affects the anaplastic lymphoma kinase (ALK) gene.

Crizotinib is also being studied in the treatment of other types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Crizotinib Continues to Show Promise for Some Lung Tumors, Faces Challenge of Drug Resistance - Important clinical trial results for this drug, background information, and how the trial was done.

FDA Approves New Drugs to Treat Skin, Blood, and Lung Cancers - Information about the use of this drug to treat cancer.

For Lung Cancer, a New Drug and a Way Forward - Information about the use of this drug to treat cancer.

Find Clinical Trials for Crizotinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top